SEC Form 4 · accession 0000919574-18-003209
KIORA PHARMACEUTICALS INC · KPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
ARMISTICE CAPITAL, LLC
10% Owner
Armistice Capital Master Fund Ltd.
10% Owner
Steven Boyd
10% Owner
Period of report
Apr 25, 2018
Accepted (ET)
Apr 27, 2018 · 5:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001372514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3,F1 | Apr 25, 2018 | P | 85,522 | $0.5408 | A | 16,332,500 | D | |
| Common StockF2 | Apr 25, 2018 | P$0 | 0 | $0.00 | A | 16,332,500 | I | See Footnote |
| Common StockF2 | Apr 25, 2018 | P$0 | 0 | $0.00 | A | 16,332,500 | I | See Footnote |
| Common StockF4,F1 | Apr 26, 2018 | P | 80,000 | $0.5377 | A | 16,412,500 | D | |
| Common StockF2 | Apr 26, 2018 | P$0 | 0 | $0.00 | A | 16,412,500 | I | See Footnote |
| Common StockF2 | Apr 26, 2018 | P$0 | 0 | $0.00 | A | 16,412,500 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are directly owned by Armistice Capital Master Fund, Ltd.
- F2The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F3This constitutes the weighted average purchase price. The prices range from $0.5363 to $0.5459. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F4This constitutes the weighted average purchase price. The prices range from $0.5160 to $0.5519. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.